At the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, Johnson & Johnson will present data from 2 major studies that support the performance of its recently FDA-approved Tecnis PureSee purely refractive extended depth of focus (EDOF) intraocular lens (IOL).
Additional presentations will showcase positive results from the broader Tecnis family of IOLs—including evidence of their high tolerance to refractive error and range of vision. According to the company, new data for Tecnis Odyssey IOL reveal high tolerance in patients with astigmatism, including high spectacle independence, and low rates of severe dysphotopsias. Additionally, new data from the Veritas Vision System showed no measurable endothelial cell count loss, the company said.
Notable Findings for Tecnis PureSee IOL
Results from a US prospective, randomized clinical trial involving over 200 patients across 9 sites show high-quality distance visual acuity, significantly improved intermediate vision vs the monofocal control Tecnis 1-pc IOL, and some near vision gained while maintaining contrast sensitivity comparable to an aspheric monofocal IOL and low levels of visual symptoms. Three datasets will be highlighted at the meeting:
1. Quality of Vision Clinical Outcomes for a New Extended Depth of Focus Intraocular Lens; Eric D. Donnenfeld, MD, FACS (Abstract). This dataset evaluates the quality of vision of a new purely refractive extended depth of focus IOL in comparison to a standard aspheric monofocal IOL. Data shows Tecnis PureSee IOL provided low rates of visual disturbances and improved intermediate and near vision with higher spectacle independence compared to a monofocal IOL while maintaining contrast sensitivity and comparable distance vision acuity with pupil independent performance.
2. Depth of Focus and Visual Performance of a New Purely Refractive Extended Depth of Focus (EDOF) IOL– Daniel Chang DH, MD (Abstract). This dataset evaluates the visual performance and patient reported outcomes of Tecnis PureSee IOL as compared to a standard aspheric monofocal IOL. It shows strong distance-corrected intermediate vision of 20/28 (mean monocular); some near vision gained with 1.5 lines of difference over control; and a broader range of clear focus, pupil independence performance, and overall spectacle independence in most subjects in the Tecnis PureSee IOL group.
3. Comparison of Tolerance to Refractive Error of a New Purely Refractive Extended Depth of Focus (EDOF) IOL and Standard Monofocal IOL – Vance M. Thompson, MD (Abstract). This dataset evaluates the clinical tolerance to refractive error of a new purely refractive EDOF IOL as compared to a standard aspheric monofocal IOL. Results show that 94% of patients saw distance corrected at 20/25 or better under defocus up to +/- 0.5 D, which indicates good tolerance to refractive error (mean binocular). Additional subgroup analysis showed 97% of EDOF and 94% of control patients were completely or mostly satisfied with their uncorrected overall vision. This subgroup analysis also showed 92% of EDOF and 87% of control patients with refractive errors in at least 1 eye did not need spectacle correction for distance.
To further support the clinical data for Tecnis PureSee IOL, Johnson & Johnson said it will also share results from a real-world, postmarket observation study from more than 700 patients across 19 sites in Europe and Asia-Pacific that show excellent clinical outcomes, low bothersome visual symptoms, and high patient satisfaction with limited spectacle use. The lens also demonstrated a high tolerance to post-op refractive errors, the company noted.
Three datasets featured:
1. Real-World Quality of Vision Outcomes in Patients Implanted with a Purely Refractive Extended Depth of Focus IOL – Brian Schwam, MD, ABO (Abstract). Data reports multicentric real-world quality of vision results of a purely refractive EDOF PCIOL. It shows mean binocular uncorrected distance vision of 20/19 and best corrected distance vision of 20/18. The data also show mean binocular uncorrected intermediate and distance corrected intermediate vision of 20/26. Most patients experienced little or no bothersome glare (91%), halos (93%), and (92%) starbursts, respectively.
2. Real-World Spectacle Independence and Visual Outcomes in Patients Implanted with a Purely Refractive Extended Depth of Focus IOL – Naren Shetty, MS, PhD (Abstract). Data reports multicentric real-world spectacle independence and visual outcomes of a purely refractive EDOF PCIOL. The data show mean binocular uncorrected distance vision was 20/19 and best corrected distance vision was 20/18. Spectacle independence was reported in 96% of patients for distance, 95% for intermediate, and 61% for near; and 93% patient satisfaction across all distances.
3. Real-World Performance of New Purely Refractive Extended Depth of Focus (EDOF) IOL in Patients with Residual Post-Op Refractive Error – Habeeb Ahmad, MD, MS, ABO (Abstract). Data evaluates the clinical tolerance to residual refractive errors of a new purely refractive Tecnis EDOF IOL. It shows mean binocular uncorrected distance vision was 20/19 in both groups (ametropic and emmetropic). Most patients reported spectacle independence at distance (91% ametropic and 96% emmetropic); and 95% of ametropic and 92% of emmetropic patients were satisfied with their uncorrected overall vision.
Additional Tecnis IOLs will be featured via investigator-initiated studies (IIS):
Clinical Outcomes Following Bilateral Implantation of a Next-Generation Intraocular Lens in Patients with Primary Open Angle Glaucoma (POAG); Yuen, MD - (Abstract). Results in an observational study of visual outcomes following bilateral Tecnis Odyssey IOL implantation in eyes with POAG showed 90% of eyes achieved uncorrected distance vision of 20/25 or better and 87% achieved uncorrected near vision of 20/25 or better.
Tolerance to Simulated Astigmatism and Patient-Reported Outcomes of a Violet Light–Filtering Diffractive Full Visual Range Intraocular Lens - Hugo F. Borges, MD, and Karolinne M. Rocha, MD, PhD, ABO (Abstract). Research showed 90% of patients with up to 1.50 D of with-the-rule astigmatism and up to 1.00 D of against-the-rule achieved distance visual acuity of 20/40 or better. In addition, 96.6% of patients achieved spectacle independence and low dysphotopsias per the AIOLIS questionnaire.
Other IIS Data:
Effective Phaco Time and Endothelial Cell Loss Using a Novel Dual Mode Phacoemulsification System - Carlton Yuen, MD, BSc, ABO (Abstract). Interim results show a low mean effective phaco time of 1.67 seconds per phacoemulsification case and no measurable loss in endothelial cells when using the Veritas Vision System. There was no change in central corneal thickness compared to baseline at 1 month post-op.